Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Euthyrox Nantong vs Darmstadt in Healthy Participants
NCT05174000Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levothyroxine sodium in hypothyroidism (2 arms), sponsored by Merck KGaA. Primary endpoints: Maximum Observed Serum Concentration, Adjusted for Baseline at 72 hours and Baseline-Corrected Area Under the Serum Concentration-Time Curve from Time Zero to 72 hours Post-dose. Started Jan 2022; status: completed.
02
Drugs
levothyroxine sodium
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on NCT05174000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174000.